Abeona Therapeutics(US:ABEO) Newsfilter·2024-08-01 11:30Company Overview - Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases [2] - The company is currently developing Prademagene zamikeracel (pz-cel), an investigational autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa [2] - Abeona has a fully integrated cell and gene therapy cGMP manufacturing facility that supports the production of pz-cel for its Phase 3 VIITAL™ trial and is capable of commercial production upon FDA approval [2] - The company is also working on AAV-based gene therapies for ophthalmic diseases, utilizing next-generation AAV capsids to enhance tropism profiles for various diseases [2] Recent Developments - On July 31, 2024, Abeona's Compensation Committee granted equity awards to two new non-executive employees, totaling up to 4,500 restricted shares of common stock [1] - The equity awards are structured to vest one-third yearly on each anniversary of the Grant Date, with full vesting occurring on the third anniversary, contingent on continued employment [1]